LON:RENX Renalytix Share Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Renalytix Plc Please log in to your account or sign up in order to add this asset to your watchlist. GBX 117.50 +12.50 (+11.90%) (As of 07/4/2022 12:00 AM ET) Add Compare Share Today's Range 107▼ 12050-Day Range 102.65▼ 215.5552-Week Range 98.20▼ 1,190Volume111,905 shsAverage Volume130,779 shsMarket Capitalization£87.84 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsInsider TradesHeadlines Renalytix MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestN/ADividend StrengthN/ASustainabilityN/ANews Sentiment1.21Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthN/ASee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.0.58 out of 5 stars 0.0 Analyst's Opinion Consensus RatingThere is not enough analysis data for Renalytix. Previous Next 0.0 Short Interest Short InterestThere is no current short interest data available for RENX. Previous Next 0.0 Dividend Strength Dividend YieldRenalytix does not currently pay a dividend.Dividend GrowthRenalytix does not have a long track record of dividend growth. Previous Next 0.0 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RENX. Previous Next 2.9 News and Social Media Coverage News SentimentRenalytix has a news sentiment score of 1.21. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Renalytix this week, compared to 0 articles on an average week. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Renalytix insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Renalytix is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Renalytix is -2.38, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRenalytix has a P/B Ratio of 1.19. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive RENX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Renalytix and its competitors with MarketBeat's FREE daily newsletter. Email Address About Renalytix (LON:RENX) StockRenalytix Plc develops artificial intelligence-enabled in vitro diagnostic solutions for kidney diseases. The company offers KidneyIntelX, a diagnostic platform that employs an artificial intelligence-enabled algorithm that combines various data inputs, including validated blood-based biomarkers, inherited genetics and personalized patient data from electronic health record systems to generate a unique patient risk score. Its products are used in kidney disease diagnosis and prognosis, clinical care, patient stratification for drug clinical trials, and drug target discovery. Renalytix AI plc has a license agreement with Mount Sinai Health System to develop and commercialize licensed products in connection with the application of artificial intelligence for the diagnosis of kidney disease; Joslin Diabetes Center, Inc. for developing and commercializing products for diagnosing and predicting kidney disease using biomarkers; and Kantaro Biosciences LLC for developing and commercializing laboratory tests for the detection of antibodies against SARS-CoV-2. The company also has a partnership agreement with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to implement an advanced clinical care model designed to improve kidney health and reduce kidney disease progression and kidney failure in high-risk populations. The company was formerly known as Renalytix AI plc and changed its name to Renalytix Plc in June 2021. Renalytix Plc was incorporated in 2018 and is headquartered in New York, New York.Read More RENX Stock News HeadlinesJune 30, 2022 | fool.co.ukHere’s why the Renalytix share price is tankingJune 30, 2022 | finance.yahoo.comRenalytix Reports Financial Results for Third Quarter of Fiscal Year 2022June 16, 2022 | uk.finance.yahoo.comThe Renalytix share price – where next?June 10, 2022 | finance.yahoo.com1,112 Patient Study Demonstrates Clinical Utility and Care Benefits of KidneyIntelX™ Risk Stratification in Stage 1 to 3 Diabetic Kidney Disease PatientsJune 6, 2022 | finance.yahoo.comKidneyIntelX™ Demonstrates Ability to Assess Risk of Heart Failure Hospitalization and Death in Large International Diabetic Kidney Disease Patient CohortApril 8, 2022 | finance.yahoo.comRenalytix plc successful completion of $30.0 million financing packageMarch 31, 2022 | ca.finance.yahoo.comRenalytix announces a $30.0 million financing packageMarch 10, 2022 | proactiveinvestors.comFragrant Prosperity slumps as reverse takeover falls throughFebruary 24, 2022 | finance.yahoo.comKidneyIntelX™ Clinical Results Presented at World Congress of Nephrology Demonstrate Improved Prediction of Kidney Function Over Standard of CareFebruary 22, 2022 | lse.co.ukRenalytix Plc Share ChatJanuary 11, 2022 | finance.yahoo.comPositive Study Results Published for KidneyIntelX™ in Monitoring Patient Response to New Drug TherapyJanuary 5, 2022 | finance.yahoo.comRenalytix to Present at 40th Annual J.P. Morgan Virtual Healthcare ConferenceDecember 9, 2021 | lse.co.ukRenalytix loss widens in first quarter amid higher R&D spendingNovember 9, 2021 | finance.yahoo.comSt. Joseph’s Health and Renalytix Partner to Advance Value-Based Kidney Health in New YorkOctober 8, 2021 | finance.yahoo.comRenalytix to Report Fourth Quarter and Full Year Fiscal 2021 Financial Results on October 21September 14, 2021 | finance.yahoo.comMount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX™ Enabled Health Care ModelSeptember 9, 2021 | finance.yahoo.com3 High-Growth Healthcare Stocks to Buy in SeptemberSeptember 3, 2021 | finance.yahoo.comRenalytix to Present at the 2021 Wells Fargo Virtual Healthcare ConferenceSeptember 2, 2021 | proactiveinvestors.comRenalytix PLC - Price Monitoring ExtensionAugust 30, 2021 | finance.yahoo.com3 High-Growth Stocks That Could Soar by 30% or Better According to Wall StreetAugust 30, 2021 | finance.yahoo.comRenalytix Appoints Daniel J. Levangie to its Board of DirectorsAugust 26, 2021 | finance.yahoo.comPayer Budget Impact Analysis Projects Significant Savings from KidneyIntelX™ Testing at Primary Care LevelAugust 20, 2021 | lse.co.ukJersey Oil letting go of two licencesJuly 28, 2021 | finance.yahoo.comRenalytix Appoints Ann Berman to its Board of DirectorsJuly 26, 2021 | finance.yahoo.comRenalytix to Present at the 41st Annual Canaccord Genuity Global Growth ConferenceSee More Headlines Industry, Sector and Symbol Stock ExchangeLON Industry Diagnostics & Research Sub-IndustryN/A SectorMedical Current SymbolLON:RENX CUSIPN/A CIKN/A Webwww.renalytixai.com Phone44 20 3139 2910FaxN/AEmployees51Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity Ratio0.53 Current Ratio5.73 Quick Ratio5.33 Sales & Book Value Annual Sales£2.42 million Price / Sales36.33 Cash FlowGBX 72.63 per share Price / Cash Flow1.62 Book ValueGBX 99.10 per share Price / Book1.19Miscellaneous Outstanding Shares74,760,000Free FloatN/AMarket Cap£87.84 million OptionableNot Optionable BetaN/A Renalytix Frequently Asked Questions How has Renalytix's stock performed in 2022? Renalytix's stock was trading at GBX 620 at the beginning of 2022. Since then, RENX stock has decreased by 81.0% and is now trading at GBX 117.50. View the best growth stocks for 2022 here. Who are Renalytix's key executives? Renalytix's management team includes the following people: Mr. James R. McCullough M.B.A., CEO & Exec. Director (Age 54, Pay $1.13M)Mr. Fergus Fleming, CTO & Exec. Director (Age 55, Pay $587k)Mr. Thomas H. McLain CPA, M.B.A, Pres (Age 63)Mr. Oliver James Sterling III, Chief Financial OfficerMs. Andria Parks-Herrera, VP of MarketingMs. Jean M. Casner, Sr. VP & Chief HR Officer (Age 63)Mr. Baljit Singh, Head of Clinical OperationsDr. Michael J. Donovan M.D., Ph.D., Chief Medical Officer (Age 68)Mr. Salim Hamir F.C.A., Company Sec. Who are some of Renalytix's key competitors? Some companies that are related to Renalytix include Profound Medical (PRN), Profound Medical (PRN), Akumin (AKU), SQI Diagnostics (SQD), Oncimmune (ONC), Yourgene Health (YGEN), VentriPoint Diagnostics (VPT), Verici Dx (VRCI), Cambridge Cognition (COG), GeneNews (GEN), LexaGene (LXG), genedrive (GDR), GENinCode (GENI), LED Medical Diagnostics (LMD) and Abingdon Health (ABDX). View all of RENX's competitors. What other stocks do shareholders of Renalytix own? Based on aggregate information from My MarketBeat watchlists, some companies that other Renalytix investors own include United Microelectronics (UMC), Teva Pharmaceutical Industries (TEVA), SSP Group (SSPG), Sarepta Therapeutics (SRPT), Redrow (RDW), QUALCOMM (QCOM), Lloyds Banking Group (LLOY), Entain PLC (GVC.L) (GVC), Gamma Communications (GAMA) and eHealth (EHTH). What is Renalytix's stock symbol? Renalytix trades on the London Stock Exchange (LON) under the ticker symbol "RENX." How do I buy shares of Renalytix? Shares of RENX and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. What is Renalytix's stock price today? One share of RENX stock can currently be purchased for approximately GBX 117.50. How much money does Renalytix make? Renalytix (LON:RENX) has a market capitalization of £87.84 million and generates £2.42 million in revenue each year. How many employees does Renalytix have? Renalytix employs 51 workers across the globe. How can I contact Renalytix? The official website for Renalytix is www.renalytixai.com. The company can be reached via phone at 44 20 3139 2910. This page (LON:RENX) was last updated on 7/4/2022 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply. MarketBeat Resources Premium Research Tools MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Discover All Access Market Data and Calendars Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free. View Market Data Investing Education and Resources Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more. Financial Terms Details Here
